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Purpose: Colostrum has been proposed to treat severe dryness and problematic eye
lesions showing a beneficial effect. The aim of the study was to investigate the effect of
2-fucosyl-lactose, a natural sugar present in the human colostrum, in an experimental
dry eye.
Methods: Dry eye was induced in adult male New Zealand albino rabbits by topical
administration of 1% atropine. Tear volume (Schirmer’s test), tear film breakup time
(TBUT), corneal staining and tear osmolarity were assessed. Fucosyl-lactose eye drops
was instilled at different concentrations (0.01, 0.1, and, 1%).
Results: After 24 h from first atropine administration, tear volume and TBUT values
were significantly improved in groups treated with 2-fucosyl-lactose in a dose-dependent
manner. Tear volume increased from 5.25 to 10.75 mm and TBUT values from 8.75 to
34.5 s with 0.01% or 1% 2-fucosyl-lactose treatment, respectively. No changes were
observed in terms of corneal staining among the all groups treated with 2-fucosyl-lactose.
Atropine instillation caused an increase of tear osmolarity (428 mOsm/L), which was
reversed by topical treatment with 2-fucosyl-lactose at all doses.
Conclusion: The present study demonstrated that 2-fucosyl-lactose, a human milk
oligosaccharide, has protective effect on tear film stability.
Keywords: fucosyl-lactose, dry eye, milk oligosaccharides, colostrum, nutraceutical compound
INTRODUCTION
Dry eye disease, also known as keratoconjunctivitis sicca, is a multifactorial disorder of the tears
and ocular surface. Common symptoms of dry eye disease include dryness, irritation, foreign body
sensation, light sensitivity, and itching. It is estimated that almost 5 million Americans 50 years and
older have dry eye disease, and millions more experience episodic symptoms of dry eye; of these,
approximately two-thirds are women (Smith et al., 2007). The prevalence of dry eye disease rises
dramatically with increasing age, and as older populations grow, so too will the burden of dry eye
disease-associated morbidity. The pathogenesis of dry eye disease is not fully understood; however,
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it is recognized that hyperosmolarity could affect the surface
tension and the stability of the tear film. Hyperosmolarity of
tears is an important feature that has been investigated and is
one of the strongest predictors of dry eye syndrome (Lemp et al.,
2007). Hyperosmolarity environment could contribute to trigger
an inflammatory process; it is noteworthy that inflammation has a
prominent role in the development and amplification of the signs
and symptoms of dry eye disease.
Oligosaccharides are important constituents of the human
milk most of all are fucosylated. Among all fucosylated milk
oligosaccharides, the a1,2-linked fucosylated glycans, which
require the secretor gene for expression in human milk, are
the dominant glycan structure found in the milk of secretor
mothers (Newburg, 1996; Newburg et al., 2004). Despite the role
of oligosaccharides were initially unclear, it has lately become
evident that 1,2-fucosylated milk oligosaccharides represent a
component of an innate immune system by which the lactating
mother protects her infant baby from environmental pathogens,
particularly during the first months. Viruses, bacteria and toxins
may become pathogenic after adhering to binding sites located on
the surface of intestinal epithelial cells (Coyne et al., 2005). Thus,
intestinal cells are covered with 1,2 fucosylated glycoproteins
and glycolipids protecting by pathogens (Coyne et al., 2005). A
mannosyl-fucosyl receptor on the surface of macrophages has
been described by Sarkar et al. (1996). The 2-fucosyl-lactose is
the most abundant oligosaccharide in the milk (roughly 5 g/L)
representing up to 30% of the total human milk oligosaccharides
(Erney et al., 2000; Chaturvedi et al., 2001). Interestingly, 2-
fucosyl-lactose, the first appearing oligosaccharides in human
colostrum, is synchronized with the concomitant macrophage
deactivation (Musumeci et al., 2006).
Based on the above evidences, we focused our attention to 2-
fucosyl-lactose, a constituent of colostrum, assessing the effect of
this sugar on tear film stability in an experimental dry eye model.
MATERIALS AND METHODS
Animals
Male New Zealand albino rabbits weighing 1.8–2.0 kg (Harlan,
Italy) were used. Animals were housed in single cage upon arrival
in the facilities (in a light and temperature controlled room)
with tap water and standard chow provided ad libitum. Animal
procedures followed guidelines of the Animal Care and Use
Committee of the University of Catania, and conformed to the
Association for Research in Vision and Ophthalmology (ARVO)
resolution on the use of animals in research.
Dry Eye Model
Atropine sulfate 1.0% ophthalmic solution (Atropina Lux,
Allergan, Italy) was instilled into the lower conjunctival sac
of each eye three times a day for the duration of each study.
We used atropine, a cholinergic (M3) receptor antagonist, in
order to decrease aqueous production and modify tear stability.
Fifteen minutes after atropine instillation we treated the eyes with
fucosyl-lactose eye drops or PBS. To assess the degree of dry
eye, tear volume, tear film breakup time (TBUT), and corneal
staining were used as end points. Baseline values for tear volume,
slit lamp examination of tear film, and corneal integrity were
obtained 1–2 days before the induction of dry eye according to
an established methodology (Shafiee et al., 2011). Tear volume
was evaluated by the Schirmer test (Schirmer strips by Eagle
Vision, Memphis, TN, USA). The strips were carefully placed
in the posterior (i.e., temporal) lower fornix for 60 s, and the
wetted area was read in millimeters as an index of tear volume.
TBUT was determined after instillation of 5 ml of 2% sodium
fluorescein in sterile PBS onto the lower eyelid trying to evenly
spread the eye drops on the cornea by manual blinking of the
lids. Under slit lamp (Sbisà, Firenze, Italy) with cobalt blue filter
to enhance the fluorescein patterns, the time from opening of
the eyes until the appearance of the first black spot or streak
on the cornea was recorded. The procedure was sequentially
performed three times and the average of three readings was
generated. Corneal epithelial-staining was evaluated using the
National Eye Institute grading system (Lemp, 1995). The corneal
surface was divided into five areas, 0–3 staining severity for each
area was designated, and the grades were added, providing a total
severity of 0–15. All measurements were performed in awake
animals in the following sequence: TBUT, corneal staining, and
Schirmer test. Tear osmolarity (mOsm/L) was measured, in a
separate set of animals, using an Osmomat 30 freezing-point
osmometer (Gonotech, Berlin, Germany); tear sample, collected
by a glass capillary tube, was diluted and the value generated
was then normalized (Aragona et al., 2002). Tear collection was
performed in a separate set of animals to avoid any artifact in
the assessment of TBUT, corneal staining and Schirmer test.
Five groups of animals (four animals/group) were used and
treated as following: (1) control (none treatment); (2) vehicle
(atropine treatment + eye drops vehicle); (3) 0.01% Fucosyl-
lactose (atropine treatment+ fucosyl lactose treatment); (4) 0.1%
Fucosyl-lactose (atropine treatment + fucosyl lactose treatment);
(5) 1% Fucosyl-lactose (atropine treatment + fucosyl lactose
treatment).
Statistical Analysis
All data are expressed as mean  SD unless indicated otherwise.
Statistical analysis was conducted using ANOVA followed by the
Dunnett’s test. A p-value< 0.05 was considered significant.
RESULTS
Atropine’s action is related to a pharmacological antagonism to
muscarinic receptors in the lacrimal gland that cause a significant
decrease of aqueous production with an evident modification of
tear stability. It has been described (Stern et al., 1998) that ocular
surface (cornea, conjunctiva, and accessory lacrimal glands),
Meibomian glands, and main lacrimal gland, are interconnected
by neural reflex loops that maintain an integrated “functional
unit.” The neural reflex loops involved in maintaining the normal
tear physiology can be blocked by anticholinergic agents such as
atropine, as demonstrated by Schoenwald et al. (1998) in a rabbit
dry eye model.
Multiple topical administration of atropine significantly
reduced tear volume (3.75  0.5 mm) compared with baseline
(12.5  0.5 mm) after 24 h (Table 1). Fucosyl-lactose (0.01, 0.1,
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TABLE 1 | Tear volume (Schirmer test) and tear break up time (TBUT) after 24 h from the first atropine administration.
No atropine Atropine
Control Vehicle 0.01% Fucosyl-lactose 0.1% Fucosyl-lactose 1% Fucosyl-lactose
Schirmer test (mm)
12.5  0.5 3.75  0.5* 5.25  0.5* 7.75  0.9* 10.75  0.9*
TBUT (sec)
>60 4.75  0.9* 8.75  0.9* 18.5  1.0* 34.5  1.3*
*p<0.05 vs. vehicle; n=6–8.
TABLE 2 | Tear osmolarity after 24 h from the first atropine administration.
No atropine Atropine
Control Vehicle 0.01% Fucosyl-lactose 0.1% Fucosyl-lactose 1% Fucosyl-lactose
Tear osmolarity (mOsm/L)
335  12 428  36* 349  29* 330  18* 322  14*
*p<0.05 vs. vehicle; n=6–8.
and 1.0%) significantly inhibited atropine-induced tear volume
reductions after 24 h in a dose-dependent manner (Table 1). The
highest dose of fucosyl-lactose eye drops maintained tear volume
near the baseline levels. These data indicate that the treatments
completely prevented atropine-mediated effects in tear volume.
When evaluating the tear integrity of atropine-treated eyes as
measured by TBUT, trends similar to those observed in tear
volume were identified.
Atropine-treated eyes showed a robust reduction in terms
of TBUT at 24 h (around 5 s) when compared with control
(35 s). Fucosyl-lactose (0.01, 0.1, and 1.0%) significantly inhibited
atropine-induced TBUT reduction after 24 h in a dose-dependent
manner (Table 1). Fucosyl-lactose (1%) eye drops maintained
TBUT at high levels when compared to vehicle group (Table 1).
All together these data demonstrated that topical treatment with
fucosyl-lactose prevented the effects of atropine on tear stability.
It is also well known that an increased tear film osmolarity
causing ocular surface damage, therefore, tear osmolarity was
assessed in rabbit with dry eye with or without fucosyl-lactose
treatment. Atropine instillation caused a significant increase of
tear osmolarity, which was significantly reversed by fucosyl-
lactose topical treatment with a trend that suggest a dose-
dependent manner, although there is no significant difference in
the three formulations (Table 2).
In the present study corneal staining was not reduced by
fucosyl-lactose in atropine-treated eyes (data not shown).
DISCUSSION
The results of the present study suggest that 2-fucosyl-lactose eye
drops might be effective for the dry eye disease. Fucosyl-lactose
improved ocular surface integrity, increased tear volume and
restored the tear osmolarity. The ocular surface system consists
of the cornea, conjunctiva, lacrimal glands, meibomian glands,
nasolacrimal duct, and their associated tear and connective tissue
matrices, as well as the eyelids and eyelashes, all integrated
by continuous epithelia and interconnected nervous, endocrine,
immune, and vascular systems. Factors that perturb the fine
homeostatic balance of the ocular surface system can adversely
affect tear film stability resulting in inflammatory damage.
Tear film instability and tear hyperosmolarity are considered
core mechanisms in the development of dry eye. It has been
demonstrated that hyperosmolar levels in the tear film may
transiently spike during tear instability, resulting in corneal
inflammation (Liu et al., 2009). Hyperosmolarity is recognized
to be an important mechanism within the etiology of dry
eye disease. Hence, hyperosmolarity represents one of the key
mechanism to trigger the machinery of ocular surface pathology
produced within dry eye syndrome, principally through eliciting
inflammation, cell death, and destabilizing the tear film (Lemp
et al., 2007). Animal models of dry eye that employ either anti-
cholinergic agents and environmental stress show that ocular
surface discomfort can induce the inflammatory/T-cell alterations
seen in human dry eye. Evidence suggests that inflammation
induced by desiccating stress is mediated by T-cells (Knop
et al., 2008; Zheng et al., 2010; Zhang et al., 2011). Like other
tissues, the eye contains a unique immunoregulatory network
designed to limit bystander tissue damage during microbial
insults and maintain tolerance to self-antigens and commensal
microbes. The eye, like the gut, contains its own local lymphoid
tissues, i.e., conjunctiva-associated lymphoid tissue (CALT),
situated to sample antigens and maintain tolerance to commensal
flora (Newburg et al., 2005; Knop et al., 2008). Alterations in
one or several components of the ocular surface system or
its secretions results in changes in the tear film or corneal
epithelial surface composition (e.g., tear osmolarity and tear
volume), leading to susceptibility to desiccation and epithelial
damage. In humans tear film osmolarity is increased in all
forms of dry eye and tear volume is decreased in aqueous-
deficient dry eye. There has been an adequate increase in
knowledge regarding the pathophysiology of dry eye in the
last years, however there are several unmet points in terms of
dry eye treatment. We demonstrated, for the first time, that 2-
fucosyl-lactose, a natural sugar present in the human colostrum,
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prevents tear film instability. Okano and collaborators have
recently demonstrated that fucose-containing carbohydrates
are able to induce a Th2 response (Okano et al., 2001). It is
noteworthy that with different ethnicity there is also different
milk oligosaccharide profiles, in particular 2-fucosyl-lactose
varies among individuals and over the course of lactation,
and may occur in even higher concentrations in colostrum
(Coppa et al., 1999). Recently, it has been demonstrated that
colostrum from Burkinabe women have significantly higher
levels of 2-fucosyl-lactose compared with Italian women
colostrum (Sotgiu et al., 2006). A comparable percentage of
the secretor genotype for the Lewis blood group phenotype
in both Burkinabe and Italian women was found. It is
noteworthy that Burkinabe women used to instill some drops
of colostrum to the newborn; this represents a community
heritage. It has been recently demonstrated that 2-fucosyl-
lactose possess immune-modulating effects, which are able to
reduce the proliferation and detrimental cytokines production
from peripheral lymphocytes through a macrophage-mediated
inhibition (Sotgiu et al., 2006). Two decades ago, Chaumeil
et al. (1994) proposed colostrum to treat severe dryness and
problematic eye lesions showing a beneficial effect. Our data
showed that topical 2-fucosyl-lactose is an effective molecule
when tested in experimental atropine-induced dry eye model
in rabbit. In particular, fucosyl-lactose significantly inhibited
atropine-induced tear volume (e.g., 1% fucosyl-lactose-treated
group 10.75 vs. 3.75 mm vehicle-treated group) and TBUT (e.g.,
1% fucosyl-lactose-treated group 34.5 vs. 4.75 s vehicle-treated
group) reduction after 24 h in a dose-dependent manner.
Because the mechanisms underlying the therapeutic effects
of topical 2-fucosyl-lactose administration remain unclear,
further research, such as controlled studies with placebo or
with current treatment, is required to establish which is the
added value of using this sugar in the treatment of dry eye
disease. However, a clue on mechanism/s come from a recent
study where the authors demonstrated that 2-fucosyl-lactose
inhibits LPS-mediated inflammation in an in vitromodel through
a sophisticated signaling pathway (He et al., 2014). These
authors showed that 2-fucosyl-lactose inhibits membrane-bound
CD14 expression, while increasing soluble form of CD14 in
the supernatant and the internalization of membrane form
of CD14. Further, 2-fucosyl-lactose increases the amounts
of negative regulatory molecules, including p-Akt, p-p38,
suppressors of cytokine signaling 2 (SOCS2), phosphorylated
signal transducer and activator of transcription 3 (pSTAT3)
and IkB, while repressing pErk and NF-kB levels (He et al.,
2014).
In conclusion, our findings support the hypothesis that 2-
fucosyl-lactose, a natural sugar present in the human colostrum,
may be useful in clinical practice to manage ocular surface
diseases.
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